Charles River Laboratories International and Purespring Therapeutics, a gene therapy company focused on revolutionizing the treatment of kidney diseases, have joined forces in a plasmid DNA contract development and manufacturing organization (CDMO) collaboration. The program aims to support the first gene therapy platform targeting renal diseases, which affect around 10% of the global population, or approximately 840 million people. The collaboration will leverage Charles River's established plasmid platform, eXpDNA™, and years of experience at the Company's plasmid DNA manufacturing center of excellence. Purespring is dedicated to developing innovative therapies with the potential to halt or significantly slow chronic kidney diseases, for which there is currently no therapy available, except for dialysis or transplantation. Purespring's Adeno-Associated Virus (AAV)-based gene therapy, which focuses on the podocyte, a specialized kidney cell type implicated in many kidney diseases, offers a low-dose, local delivery approach that maximizes safety and efficacy, while reducing the cost of goods.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!